Triple-negative breast cancer--current status and future directions

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor, and HER2 expression.
• TNBC exhibits unique molecular, histological, and clinical features, often leading to a poor prognosis.
• TNBC shows high concordance with basal-like breast cancer (BLBC) identified through gene expression profiling.

Purpose of the Study:

• To summarize current therapeutic strategies and ongoing research for improving outcomes in TNBC.
• To highlight the heterogeneity within TNBC and BLBC, impacting treatment efficacy.
• To explore novel therapeutic agents and treatment optimization for TNBC patients.

Main Methods:

• Review of existing literature on TNBC and BLBC classification.
• Analysis of gene expression data to define BLBC subtypes.
• Examination of ongoing clinical trials and preclinical research for novel TNBC therapies.

Main Results:

• TNBC and BLBC are heterogeneous, contributing to incomplete concordance and varied clinical behavior.
• Despite sensitivity to chemotherapy, TNBC has an unfavorable prognosis.
• Emerging therapies include PARP inhibitors, EGFR inhibitors, multikinase inhibitors, and antiangiogenic agents.

Conclusions:

• Optimizing current chemotherapy regimens (e.g., platinum salts, dose intensification) is crucial.
• Novel targeted therapies offer promising avenues for improving TNBC patient survival.
• Further research into TNBC heterogeneity is essential for personalized treatment approaches.